Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Linear Growth”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Post-approval studies (Phase 4)Study completedNCT01609543
What this trial is testing

Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 62
Testing effectiveness (Phase 2)Study completedNCT01491737
What this trial is testing

Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 258
Large-scale testing (Phase 3)Study completedNCT00982111
What this trial is testing

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 633
Not applicableUnknownNCT00903292
What this trial is testing

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Non-Small Cell Lung Cancer
National Cheng-Kung University Hospital 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT06120140
What this trial is testing

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 305
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05559801
What this trial is testing

Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)

Who this might be right for
Osteogenesis ImperfectaOsteogenesis Imperfecta Type III
Emory University 12
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Testing effectiveness (Phase 2)Study completedNCT02444819
What this trial is testing

Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 33
Testing effectiveness (Phase 2)Study completedNCT00125034
What this trial is testing

Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Neoplasm MetastasisColorectal Cancer
Merck KGaA, Darmstadt, Germany 344
Testing effectiveness (Phase 2)Study completedNCT04188847
What this trial is testing

First-line Chemotherapy for Recurrent Cervical Cancer

Who this might be right for
Recurrent Cervical CarcinomaPersistent Advanced Cervical CarcinomaChemotherapy+3 more
Lei Li 37
Testing effectiveness (Phase 2)WithdrawnNCT05512182
What this trial is testing

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Who this might be right for
Recurrent/Advanced Gastric Cancer
Yonsei University
Testing effectiveness (Phase 2)Study completedNCT00615758
What this trial is testing

Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV

Who this might be right for
Non Small Cell Lung Cancer
Hellenic Oncology Research Group 50
Testing effectiveness (Phase 2)Looking for participantsNCT04335292
What this trial is testing

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Who this might be right for
Non-Small Cell Lung Cancer
Mark Vincent 200
Not applicableStudy completedNCT00922025
What this trial is testing

Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 186
Post-approval studies (Phase 4)Study completedNCT00395408
What this trial is testing

Linear Growth Study (0476-097)(COMPLETED)

Who this might be right for
Asthma
Organon and Co 360
Large-scale testing (Phase 3)UnknownNCT04500704
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166
Testing effectiveness (Phase 2)Study completedNCT04205630
What this trial is testing

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Who this might be right for
Endometrial Cancer
Byondis B.V. 64
Large-scale testing (Phase 3)Study completedNCT01342965
What this trial is testing

Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 217
Not applicableUnknownNCT04962360
What this trial is testing

The Effect of Nutritional Formula Supplementation on Linear Growth of Growth Hormone (GH) Treated Prepubertal Children With Idiopathic Short Stature (ISS) After 2 Years From the Beginning of GH-therapy

Who this might be right for
ISS- Idiopathic Short Stature
Rabin Medical Center 64
Next Page